NEO — NeoGenomics, Inc.

Is NEO overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Oversold As of October 3, 2026

NeoGenomics, Inc. (NEO) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Diagnostics & Research) last closed at $18.47. The rating moved from Strong Oversold to Oversold on October 2, 2026.

See all oversold Healthcare stocks →

AI analysis

NeoGenomics, Inc. (NEO) benefits from a diversified mix of clinical oncology testing and pharma services that drive recurring, higher‑value revenue and improved margin visibility. The company’s lab scale, specialized assays and pharma partnerships position it to capture demand tied to late‑stage biologics and companion diagnostics. Near‑term sentiment is muted by a risk‑off market and sector headwinds around reimbursement and capital markets. Key upside catalysts include growth in pharma services, successful commercial expansion of new assays, margin improvements from scale, and retention/expansion of large sponsor contracts. Main near‑term challenges are reimbursement policy risk, competitive pricing pressure from large labs, and volume sensitivity if patient throughput weakens.

Key factors

  • Specialized oncology diagnostics: diversified clinical and pharma-services revenue driven by growing demand for genomic and companion diagnostic testing in oncology
  • Pharma collaborations and CRO-style services: recurring, higher‑margin revenue from clinical trial and commercial testing partnerships supports topline visibility and potential margin expansion
  • Scale and lab footprint: national lab network and high-throughput platforms provide cost advantages versus smaller competitors and enable faster turnaround for oncologists and sponsors
  • Sector thematic tailwinds for late-stage biologics and specialty biotech: continued investment in late‑stage assets increases demand for diagnostic support, bioanalytic and trial testing services
  • Defensive demand profile: oncology testing is relatively resilient versus discretionary sectors, which can help performance in risk-off market environments

Risks

  • Reimbursement and pricing pressure: Medicare negotiation, PBM/insurer actions or adverse CMS policy changes could reduce realized prices for common tests
  • Volume sensitivity and macro risk: prolonged patient appointment deferrals or slower elective oncology care could materially reduce sample volumes in a risk‑off environment
  • Competition from large national labs and new entrants: Quest, LabCorp and emerging specialty diagnostics firms can pressure pricing and share
  • Concentration and execution risk in pharma services: loss of large sponsor contracts or failure to convert pipeline work into commercial recurring revenue would hurt growth
  • Operational/regulatory risk: lab inspection failures, quality-control issues or supply-chain disruptions could interrupt capacity and revenue
  • Capital markets/financing risk: cooling IPO/secondary window and higher rates could raise funding costs for M&A or capacity expansion

See today's live rating, score and targets

Members see the live hourly rating for NEO — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.